versión ISSN 1852-3862
MONTES PENA, Felipe et al. Application of low cost biomarkers score in prognosis analysis of patients with chronic heart failure. Insuf. card. [online]. 2011, vol.6, n.3, pp. 117-123. ISSN 1852-3862.
Purpose. To demonstrate that score based on low cost laboratory markers can determine prognosis of ambulatory patients with heart failure (HF). Introduction. HF is a disease known for her evolving with high mortality. Biomarkers are emerging as an important aid in the standard clinical evaluation of a variety of cardiovascular disorders, including HF. Methods. This study consists on a prospective cohort of outpatients with HF, the markers selected were: sodium, high density lipoprotein (HDL), creatinine, creatinine clearance, uric acid and hemoglobin. One point for changes in each marker was given and defined as low risk: 0-2 points, moderate risk: 3-4 points, and high risk: 5-6 points. The primary outcome was death from cardiovascular causes and secondary deaths from cardiovascular causes associated with hospitalizations for cardiovascular causes. The statistical methods used were chi-square, Student t test, Cox regression and it was used the Kaplan Meier curve analysis of events. Results. We studied 146 patients with mean age 58±13.04, 44 male patients (30.2%) and 102 female ones (69.8%). The primary outcomes were: 15 (10.2%) deaths and secondary: 54 (37%) compound events. The number of individuals according to the stage of risk: low: 68, intermediate: 63 and higher: 15. The rate of events in low, intermediate and high risk were eight (11.7%), 34 (54%) and 12 (80%), respectively. According to the risk stratification, the hazard ratio for low risk (HR=0.14, p=0.0001), moderate (HR=1.69, p=0.01) and high (HR=2.46, p=0.001). Conclusion. The multi-markers score based on markers of low cost admits prognostic stratification of patients, allowing predicting deaths and hospital admissions, and also creating a therapeutic strategy for follow-up of patients according to risk stratification.
Palabras llave : Biomarkers; Heart failure; Prognosis.